Daily Brief United States: ATRenew , Builders Firstsource, Calumet Specialty Products Par, Dogwood Therapeutics, Evolution Petroleum, GCI Liberty Class A, National Energy Services Reuni, Aethlon Medical , Veru and more

Key points (machine generated)

• ATRenew’s market capitalization has dropped 79% since its IPO in mid-2021 due to factors like the pandemic and economic slowdown.
• The company’s shift to direct retailing of refurbished devices has led to skepticism about profitability and minimal analyst coverage.
• Despite challenges, ATRenew shows potential for growth with an expected CAGR of 23.4% over the next four years.

This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

• Levels of certain harmful particles typically returned to pre-treatment levels 1-3 weeks after treatment ended, suggesting a potential benefit to patients while being treated the study is designed to examine whether an increased number of Hemopurifier treatments can help extend positive patient responses.
• The company’s goal is to build its database supporting development of the Hemopurifier as an oncology treatment and this data appears to support that goal.
• It will be important to monitor whether these observations are reproducible as the study progresses, as it is early in the clinical trial to draw definitive conclusions and the data from Cohort 1 is not statistically significant.

Key points (machine generated)

• Builders FirstSource is the largest U.S. supplier of structural building materials and services, with 2024 net sales of $16.4 billion.
• Revenue is primarily generated from new single-family construction (71%), with diverse product offerings including lumber, windows, and manufactured products.
• Analysts consider BLDR undervalued due to expected housing starts and operational efficiencies, with chairman Paul Levy recently investing $55 million in the company.

This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

• On the latest WTR Small-Cap Spotlight, we were joined by Bruce Fleming, Chief Executive Officer of Montana Renewables and our host, Tim Gerdeman, WTR’s Vice- Chair & Co-Founder, and Chief Marketing Officer.
• Montana Renewables (MR) is an unrestricted subsidiary (private JV) of Calumet (NASDAQ: CLMT) and the first large-scale sustainable aviation fuel (SAF) producer in the US.

• Fleming described MR as Montana’s largest agricultural investment. 

• On September 29, 2025, Dogwood Therapeutics, Inc. announced it had secured a worldwide, royalty free license to develop SP16 for the treatment of cancer related pain and chemotherapy induced neuropathy symptoms from Serpin Pharma.
• A Phase 1b study of SP16 in Chemotherapy Induced Peripheral Neuropathy (CIPN) that is fully funded by the National Cancer Institute is scheduled to begin patient enrollment in the first half of 2026.
• This deal expands Dogwood’s research pipeline and complements the ongoing development of Halneuron , which is currently in a Phase 2b clinical trial for Chemotherapy Induced Neuropathic Pain (CINP).

• Evolution’s business strategy is built upon three key pillars, including growing the asset base through accretive producing property acquisitions and low-risk organic development, distributing cash to shareholders through common stock dividends, and maintaining a conservative balance sheet.
• Our FY26 free cash flow estimate implies a dividend coverage ratio of 1.3x.
• On September 30, 2025, Evolution paid its 48th consecutive quarterly dividend in the amount of $0.12 per share. 

Key points (machine generated)

• GCI Liberty, Inc. began trading at $32.50 per share after its spin-off from Liberty Broadband, allowing it to operate independently and unlock value.
• As Alaska’s largest telecommunications provider, GCI serves 80% of homes with high-speed services and generated over $1 billion in revenue, primarily from business customers.
• Despite initial selling pressure, GCI’s favorable EBITDA multiple and strong financial position suggest potential for significant growth and returns in the coming years.

This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

• Tender tailwinds are beginning to push NESR toward its goal of reaching an annual revenue threshold of $2 billion.
• The tailwinds include recent awards and a backlog of new business opportunities. For reference, our current FY25 revenue estimate is ~$1.3 billion.
• Since April 2025, NESR has announced contract awards totaling more than $600 million.

• Levels of certain harmful particles typically returned to pre-treatment levels 1-3 weeks after treatment ended, suggesting a potential benefit to patients while being treated the study is designed to examine whether an increased number of Hemopurifier treatments can help extend positive patient responses.
• The company’s goal is to build its database supporting development of the Hemopurifier as an oncology treatment and this data appears to support that goal.
• It will be important to monitor whether these observations are reproducible as the study progresses, as it is early in the clinical trial to draw definitive conclusions and the data from Cohort 1 is not statistically significant.

• On our latest WTR Healthcare Happenings podcast, we welcomed back Mitch Steiner, CEO of Veru, Inc. (NASDAQ: VERU) to fill us in on the company’s latest significant developments and progress made since his previous appearance on our podcast in February 2025.
• Having divested its sexual health business for $18 million last year, Veru has pivoted toward the burgeoning obesity market with its lead drug candidate enobosarm, which selectively causes fat loss, while preserving lean mass in patients taking GLP-1 for weight loss.
• The state of the GLP-1 market for obesity. Steiner offered his take on the latest trends in the rapidly evolving GLP-1 market for weight loss.